Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

253.92 -1.28 (-0.50%)
Streaming Delayed Price Updated: 10:16 AM EDT, Jul 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ascendis Pharma A/S - Ordinary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >
Ascendis Pharma (ASND) Shows High Growth Momentum With Bull Flag Breakout Setup ↗
Via Chartmill
ASCENDIS PHARMA A/S (NASDAQ:ASND) Screens as a High-Growth Momentum Candidate ↗
Via Chartmill
News headline image
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Energy Fund Yielding 7% and Up 14% in a Year Still Wasn’t Enough to Stop This $3 Million Exit ↗
The Kayne Anderson Energy Infrastructure Fund targets U.S. energy infrastructure, emphasizing income from MLPs and related equities. 
Via The Motley Fool
Topics Regulatory Compliance
Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss ↗
Via Chartmill
Topics Earnings
ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
A Look Ahead: Ascendis Pharma's Earnings Forecast ↗
 
Via Benzinga
News headline image
Ascendis (ASND) Q1 2026 Earnings Call Transcript ↗
Ascendis (ASND) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL... 
Via MarketMinute
Topics Economy
News headline image
Agriculture Stock Up 53% Draws $12 Million Bet. Here's What Long-Term Investors Should Know ↗
This agribusiness firm delivers grain, renewables, and plant nutrient solutions to commercial and industrial clients worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ascendis (ASND) Q4 2025 Earnings Call Transcript ↗
Ascendis (ASND) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗
Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology. 
Via The Motley Fool
News headline image
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript ↗
Ascendis Pharma (ASND) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan ↗
Ascendis Pharma (ASND) meets Mark Minervini's strict criteria, showing a powerful technical uptrend paired with explosive revenue growth over 269%. 
Via Chartmill
News headline image
Why Dyne Therapeutics Stock Was Crushing it This Week ↗
The company has solid potential with its development of drugs targeting muscle disorders. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility
European American Depositary Receipts (ADRs) have recently experienced a period of significant fluctuation, reflecting a broader climate of market volatility that has ripple across global financial... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Ascendis (ASND) Q3 2025 Earnings Call Transcript ↗
Ascendis (ASND) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
Looking Into Ascendis Pharma AS's Recent Short Interest ↗
 
Via Benzinga
News headline image
Ascendis Pharma A/S - ADR (NASDAQ:ASND) Shows Strong Growth Momentum in Technical and Fundamental Analysis ↗
Ascendis Pharma (ASND) is a high-growth stock with strong technical uptrends and impressive fundamentals, including surging revenue and earnings momentum. 
Via Chartmill
News headline image
What Does the Market Think About Ascendis Pharma AS? ↗
Ascendis Pharma AS's (NYSE: ASND) short interest as a percent of float has fallen 14.63% since its last report. According to exchange reported data, there are now 2.29 million shares sold short, which... 
Via Benzinga
News headline image
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today ↗
Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past 10 years by 13.64% on an annualized basis producing an average annual return of 26.77%. Currently, Ascendis Pharma has a market... 
Via Benzinga
News headline image
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment ↗
BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study. 
Via Benzinga
News headline image
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.